Gå direkt till innehåll
Scandinavian Biopharma continuous the tradition of donating food to orphanages in Grand Popo, Benin!

Pressmeddelande -

Scandinavian Biopharma continuous the tradition of donating food to orphanages in Grand Popo, Benin!

For several years we have supported the orphanages in Grand Popo by donating food, medicine and other supplies to improve the situation of the children. The corona pandemic has resulted in a shortage of food supplies in the orphanages in Grand Popo as the traditional donors have not had the financial means during the pandemic.

Our Seasonal gift will guarantee that the children at the orphanages have a proper supply of rice, beans, spaghetti, tomatoes and cooking oil. We are committed to support children in low- and middle-income countries and the seasonal gift is just one of several donations during the last year. Scandinavian Biopharma did successfully conduct a Phase 2b trial of ETVAX® with Finish travellers travelling to the village of Grand Popo.

Ämnen

Kategorier


About Scandinavian Biopharma
Scandinavian Biopharma is a research-based specialty biopharma company determined to give people all over the world a longer and better life. Together with researchers at the University of Gothenburg and the international non-profit organization PATH, Scandinavian Biopharma is developing the first vaccine against ETEC which causes diarrhoea in both travellers and endemic populations.

The development project is mainly funded by the EDCTP programme, which is supported under Horizon 2020, the European Union’s (EU) Framework Programme for Research and Innovation, as well as by PATH and the U.S. Army (USAMMDA).

Scandinavian Biopharma also acts as a distributor for a wide range of specialty biopharma products in Europe with a focus on vaccines and immunoglobulins.

About ETEC
Enterotoxigenic Escherichia coli, or ETEC, is a major cause of bacterial diarrhoeal disease. ETEC infections are particularly common in low- and middle-income countries (LMIC). In children younger than 5 years, it has been estimated that 1.7 billion episodes of diarrhoea occur annually. ETEC represents a major cause of these episodes and accounts for approximately 400 000 deaths among children living in LMICs. In addition, diarrhoea is associated with an increased risk of stunting (i.e. impaired growth and development). Stunting affects cognitive development which might determine a child’s ability to learn, their educational attainment, and future earnings and it also puts children at risk due to other severe infectious diseases.

ETEC is also the leading cause of travellers’ diarrhoea, affecting more than 35 million travellers every year.

About ETVAX®

To date, no vaccine against ETEC exists and ETVAX® is the only ETEC vaccine candidate in late-stage development. The strong immunogenicity and safety data, as well as the promising field efficacy data, clearly distinguish ETVAX® as the lead vaccine candidate against ETEC. Successful development of this vaccine will address a huge unmet medical need for children in LMICs as well as for travellers.

www.scandinavianbiopharma.se

Kontakter

Relaterat innehåll

  • Scandinavian Biopharma fortsätter traditionen att donera mat till barnhem i Grand Popo, Benin!

    Scandinavian Biopharma fortsätter traditionen att donera mat till barnhem i Grand Popo, Benin!

    Under flera år har vi stöttat barnhemmen i Grand Popo genom att donera mat, medicin och andra förnödenheter för att förbättra barnens situation. Vår gåva kommer att garantera att barnen har ordentlig tillgång på ris, bönor, spagetti, tomater och matolja. Vi har åtagit oss att stödja barn i låg- och medelinkomstländer och julgåvan är bara en av flera donationer vi gjort under det senaste året.